TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19450818

Group type: EXPERIMENTAL
Intervention: (99m)technetium dimercapto-succinic acid scintigraphy
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: (99m)technetium dimercapto-succinic acid scintigraphy with parallel hole collimator
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: (99m)technetium dimercapto-succinic acid scintigraphy with pinhole imaging
Number of subjects: 70
Study: 17093998

Group type: EXPERIMENTAL
Intervention: Pars plana vitrectomy with ILM peeling (ILM group)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Modified grid laser photocoagulation (laser group)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both groups (ILM and laser)
Number of subjects: 24
Study: 15019536

Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Number of subjects: 395

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 395
Study: 11284796

Group type: EXPERIMENTAL
Intervention: Specific immunotherapy (SIT) with standardized extracts of house-dust mite for 3 years
Number of subjects: 27
Study: 9222184

Group type: EXPERIMENTAL
Intervention: Ketamine 0.10 mg/kg/hr
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ketamine 0.40 mg/kg/hr
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ketamine 0.60 mg/kg/hr
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 7702801

Group type: EXPERIMENTAL
Intervention: Intravenous saline load (2 L of 0.9% NaCl over 4 h)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Dietary salt repletion (220 mmol/day NaCl)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Low-salt diet (20 mmol NaCl) with furosemide (3 x 40 mg, po)
Number of subjects: 22
Study: 3138220

Group type: EXPERIMENTAL
Intervention: Hyperthermia plus definitive radiotherapy (60 Gy delivered in 1.8‐2.0 Gy fractions 5 times/week with a boost of 5‐10 Gy through reduced portals to residual tumor; hyperthermia delivered twice weekly for 60 minutes at 43 degrees C)
Number of subjects: 117
Study: 31782493

Group type: EXPERIMENTAL
Intervention: Responsive Parenting (RP) intervention
Number of subjects: 117

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 117
Study: 29971593

Group type: EXPERIMENTAL
Intervention: Terlipressin (20-160 µg/h, maximum infusion rate of 4 mg/day)
Number of subjects: 617

Group type: COMPARATOR
Intervention: Norepinephrine (4-30 µg/min)
Number of subjects: 617

Group type: EXPERIMENTAL
Intervention: Terlipressin
Number of subjects: 617

Group type: COMPARATOR
Intervention: Norepinephrine
Number of subjects: 617
Study: 27242081

Group type: EXPERIMENTAL
Intervention: CRC screening decision aid
Number of subjects: 262

Group type: COMPARATOR
Intervention: Food safety video (control)
Number of subjects: 262
Study: 25903799

Group type: EXPERIMENTAL
Intervention: TES program for screening and treatment of psychological distress
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TES program
Number of subjects: 0
Study: 24119004

Group type: EXPERIMENTAL
Intervention: Older Women (intervention group)
Number of subjects: 260

Group type: COMPARATOR
Intervention: Younger Women (control group)
Number of subjects: 260
Study: 20927506

Group type: EXPERIMENTAL
Intervention: Cryo/Cuff (3 × 10 min twice daily)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Cryo/Cuff
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control
Number of subjects: 52
Study: 18214724

Group type: EXPERIMENTAL
Intervention: Cocaine medication trials
Number of subjects: 255
Study: 16778696

Group type: EXPERIMENTAL
Intervention: Active conservative treatment (two regimens lasting 8 weeks)
Number of subjects: 181
Study: 14575968

Group type: EXPERIMENTAL
Intervention: Epoetin beta 300 IU/kg three times weekly
Number of subjects: 351

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Epoetin beta
Number of subjects: 351
Study: 10227414

Group type: EXPERIMENTAL
Intervention: Mass mailing recruitment strategy
Number of subjects: 4736

Group type: EXPERIMENTAL
Intervention: Experienced recruitment coordinators
Number of subjects: 4736

Group type: EXPERIMENTAL
Intervention: Total time spent on recruitment
Number of subjects: 4736
Study: 8726899

Group type: EXPERIMENTAL
Intervention: Discussion groups
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Skills training
Number of subjects: 218

Group type: COMPARATOR
Intervention: Control groups
Number of subjects: 218
Study: 1655315

Group type: EXPERIMENTAL
Intervention: CO2-laser vaporization
Number of subjects: 50

Group type: COMPARATOR
Intervention: Routine control
Number of subjects: 50
Study: 6870162

Group type: EXPERIMENTAL
Intervention: Trypure
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Varidase
Number of subjects: 38
Study: 31976804

Group type: EXPERIMENTAL
Intervention: Hebbian-type stimulation (trainingHebb)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham stimulation (trainingsham)
Number of subjects: 20
Study: 30788809

Group type: EXPERIMENTAL
Intervention: PEEP of 7 cmH2O (group P)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Zero end-expiratory pressure (group Z)
Number of subjects: 67
Study: 29292310

Group type: EXPERIMENTAL
Intervention: Tailored cessation intervention for smokers (Ps/Cs)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 110
Study: 26814235

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure management (target systolic blood pressure <140 mm Hg)
Number of subjects: 2653

Group type: COMPARATOR
Intervention: Guideline-based blood pressure management (systolic blood pressure <180 mm Hg)
Number of subjects: 2653
Study: 24788342

Group type: EXPERIMENTAL
Intervention: GOLD 1 COPD
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: GOLD 2 COPD
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: GOLD 1 and 2 COPD
Number of subjects: 208
Study: 23171095

Group type: EXPERIMENTAL
Intervention: Endovascular repair
Number of subjects: 881

Group type: COMPARATOR
Intervention: Open repair
Number of subjects: 881
Study: 20358390

Group type: EXPERIMENTAL
Intervention: Topical SLS 0.25%
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Topical SLS 0.5%
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Topical SLS 1%
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Topical SLS 2%
Number of subjects: 8

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Topical capsaicin 1%
Number of subjects: 8
Study: 17965059

Group type: EXPERIMENTAL
Intervention: Itopride 100 mg three times daily
Number of subjects: 1170

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1170
Study: 15837826

Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment
Number of subjects: 28356
Study: 12578875

Group type: EXPERIMENTAL
Intervention: Serum soluble ST2 levels measured at trial enrollment and 2 weeks after enrollment
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Baseline BNP levels
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Baseline ProANP levels
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Change in ST2 levels
Number of subjects: 161
Study: 11347858

Group type: EXPERIMENTAL
Intervention: lacidipine 4 mg o.d. (increased to 6 mg if needed)
Number of subjects: 62

Group type: COMPARATOR
Intervention: amlodipine 5 mg o.d. (increased to 10 mg if needed)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: lacidipine 6 mg (for patients requiring dose increase)
Number of subjects: 62

Group type: COMPARATOR
Intervention: amlodipine 10 mg (for patients requiring dose increase)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: lacidipine
Number of subjects: 62

Group type: COMPARATOR
Intervention: amlodipine
Number of subjects: 62
Study: 8973988

Group type: EXPERIMENTAL
Intervention: 7-day 17 beta-estradiol transdermal delivery system (TDS) applied to the abdomen
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 7-day 17 beta-estradiol transdermal delivery system (TDS) applied to the buttocks
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Early TDS replacement on day 17
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Repeated TDS applications to the buttocks
Number of subjects: 18
Study: 1316059

Group type: EXPERIMENTAL
Intervention: 400 mg lomefloxacin orally once daily (n = 259)
Number of subjects: 522

Group type: COMPARATOR
Intervention: 250 mg cefaclor every 8 hours (n = 263)
Number of subjects: 522

Group type: EXPERIMENTAL
Intervention: 400 mg lomefloxacin
Number of subjects: 522

Group type: COMPARATOR
Intervention: 250 mg cefaclor
Number of subjects: 522
Study: 3909840

Group type: EXPERIMENTAL
Intervention: Neuroleptanaesthesia
Number of subjects: 51

Group type: COMPARATOR
Intervention: Continuous thoracic epidural anesthesia
Number of subjects: 51
Study: 31496390

Group type: EXPERIMENTAL
Intervention: Dual task paradigm (simultaneous working memory task)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Focus on accuracy in decision making
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Focus on speed in decision making
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Manipulating intertrial interval (more time to learn from feedback)
Number of subjects: 0
Study: 29438199

Group type: EXPERIMENTAL
Intervention: Maraviroc intensified ART (Arm2: abacavir-lamivudine and darunavir/ritonavir/maraviroc)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard ART (Arm1: tenofovir-emtricitabine and atazanavir/ritonavir)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard ART (Arm1)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Maraviroc intensified ART (Arm2)
Number of subjects: 60
Study: 27210035

Group type: EXPERIMENTAL
Intervention: Ivabradine
Number of subjects: 1186
Study: 24912466

Group type: EXPERIMENTAL
Intervention: Ratings based on entire therapy sessions
Number of subjects: 84

Group type: COMPARATOR
Intervention: Ratings based on session segments (middle third of entire sessions)
Number of subjects: 84
Study: 22391940

Group type: EXPERIMENTAL
Intervention: UVB exposure in a commercial tanning bed (UVB/UVA ratio 1.8‐2.0%)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo tanning bed without UVB
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: UVB exposure in a commercial tanning bed
Number of subjects: 20
Study: 20364565

Group type: EXPERIMENTAL
Intervention: Meronem
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Mero
Number of subjects: 16
Study: 18246429

Group type: EXPERIMENTAL
Intervention: Second-generation antipsychotics (SGAs: olanzapine, quetiapine, risperidone, ziprasidone)
Number of subjects: 1121

Group type: COMPARATOR
Intervention: First-generation antipsychotic (FGA: perphenazine)
Number of subjects: 1121
Study: 15766337

Group type: EXPERIMENTAL
Intervention: Fixed dose regimen of diamorphine 0.4 mg in hyperbaric bupivacaine 0.5% 2.4 ml
Number of subjects: 100

Group type: COMPARATOR
Intervention: Adjusted dose regimen of diamorphine 0.4 mg in hyperbaric bupivacaine 0.5%
Number of subjects: 100
Study: 12527943

Group type: EXPERIMENTAL
Intervention: BB-10010 with dose-intensified BEMOP/CA chemotherapy
Number of subjects: 13

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 13
Study: 11029510

Group type: EXPERIMENTAL
Intervention: Aromatase inhibitors (letrozole, anastrozole, exemestane)
Number of subjects: 0
Study: 9165692

Group type: EXPERIMENTAL
Intervention: BY841 (50 mg or 100 mg twice daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Omeprazole (standard dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ranitidine
Number of subjects: 0
Study: 10148879

Group type: EXPERIMENTAL
Intervention: Patient-controlled administration of fentanyl (n=37)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Nurse administration on demand (n=43)
Number of subjects: 80
Study: 2579257

Group type: COMPARATOR
Intervention: Fluorouracil
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Fluorouracil plus doxorubicin (FA)
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Fluorouracil plus doxorubicin plus mitomycin (FAM)
Number of subjects: 305
Study: 30579673

Group type: EXPERIMENTAL
Intervention: Dietary intervention to reduce sodium intake
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 0
Study: 30303108

Group type: EXPERIMENTAL
Intervention: Molecular point-of-care testing for C trachomatis and N gonorrhoeae
Number of subjects: 455

Group type: COMPARATOR
Intervention: Standard care (routine laboratory-based testing)
Number of subjects: 455
Study: 26795538

Group type: EXPERIMENTAL
Intervention: Mailings and a coaching call intervention
Number of subjects: 244

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 244
Study: 25133799

Group type: EXPERIMENTAL
Intervention: IMID training
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: IMID training and OSS combined
Number of subjects: 36

Group type: COMPARATOR
Intervention: OSS
Number of subjects: 36
Study: 22444188

Group type: EXPERIMENTAL
Intervention: μ-opioid agonist alfentanil
Number of subjects: 224

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 224
Study: 20047672

Group type: EXPERIMENTAL
Intervention: Mini booster (two telephone calls one month apart)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Full booster (face-to-face meeting with facilitator at the same intervals)
Number of subjects: 600

Group type: COMPARATOR
Intervention: No booster (control group)
Number of subjects: 600
Study: 17209211

Group type: EXPERIMENTAL
Intervention: Folic acid supplementation at 4 mg/d for high-risk women and 0.4 mg/d for others
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Folic acid fortification mandated in the United States and some other countries
Number of subjects: 0
Study: 18569356

Group type: EXPERIMENTAL
Intervention: Intervention (5 a Day, the Rio Grande Way website)
Number of subjects: 755

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 755

Group type: EXPERIMENTAL
Intervention: Intervention (website use)
Number of subjects: 755
Study: 15086228

Group type: EXPERIMENTAL
Intervention: Rapid weaning from external ventricular drainage (EVD) within 24 hours with immediate closure of the EVD
Number of subjects: 81

Group type: COMPARATOR
Intervention: Gradual weaning from external ventricular drainage (EVD) over a 96-hour period
Number of subjects: 81
Study: 12182055

Group type: EXPERIMENTAL
Intervention: L-thyroxine suppressive therapy
Number of subjects: 4

Group type: COMPARATOR
Intervention: L-thyroxine replacement therapy
Number of subjects: 4
Study: 9408856

Group type: EXPERIMENTAL
Intervention: Mizolastine (tablet)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Mizolastine (capsule)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Mizolastine (intravenous infusion)
Number of subjects: 18
Study: 8358281

Group type: EXPERIMENTAL
Intervention: Early Detector
Number of subjects: 1842

Group type: EXPERIMENTAL
Intervention: Coloscreen Self-Test
Number of subjects: 1842

Group type: COMPARATOR
Intervention: Haemoccult
Number of subjects: 1842

Group type: EXPERIMENTAL
Intervention: Dietary restriction
Number of subjects: 1842

Group type: EXPERIMENTAL
Intervention: No dietary restriction
Number of subjects: 1842
Study: 3302144

Group type: EXPERIMENTAL
Intervention: Diet plus exercise
Number of subjects: 76

Group type: COMPARATOR
Intervention: Diet
Number of subjects: 76

Group type: COMPARATOR
Intervention: Exercise
Number of subjects: 76

Group type: COMPARATOR
Intervention: Education (control)
Number of subjects: 76
Study: 31718583

Group type: EXPERIMENTAL
Intervention: HiBalance program (balance training program emphasizing challenging exercises and dual-tasking)
Number of subjects: 100

Group type: COMPARATOR
Intervention: HiCommunication program (active control targeting speech and communication)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both interventions (HiBalance and HiCommunication)
Number of subjects: 100
Study: 28081304

Group type: EXPERIMENTAL
Intervention: ACpT (4 cycles of doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 followed by 4 cycles of paclitaxel 175 mg/m2)
Number of subjects: 1060

Group type: EXPERIMENTAL
Intervention: ACdT (4 cycles of doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 followed by 4 cycles of docetaxel 75 mg/m2)
Number of subjects: 1060

Group type: COMPARATOR
Intervention: PTx (8 cycles of paclitaxel every 3 weeks)
Number of subjects: 1060

Group type: COMPARATOR
Intervention: DTx (8 cycles of docetaxel every 3 weeks)
Number of subjects: 1060
Study: 25458980

Group type: EXPERIMENTAL
Intervention: Higher-flow nasal cannula oxygen at 15 L/minute
Number of subjects: 77

Group type: COMPARATOR
Intervention: Lower-flow nasal cannula oxygen at 6 L/minute
Number of subjects: 77
Study: 23896732

Group type: EXPERIMENTAL
Intervention: Web-based interactive decision aid
Number of subjects: 1893

Group type: EXPERIMENTAL
Intervention: Print-based decision aid
Number of subjects: 1893

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 1893

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 1893
Study: 21849400

Group type: EXPERIMENTAL
Intervention: Hand-held preoperative compact imager (POCI)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Conventional lymphoscintigraphy
Number of subjects: 162
Study: 19414676

Group type: EXPERIMENTAL
Intervention: RRS-82 (relapse-related molecular signature) identified through genome-wide expression profiling analysis
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: RRS-82 validated in an independent cohort of 30 stage I patients
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: RRS-82 validated using Duke data set
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: RRS-82 validated using another data set from the Director's Challenge Consortium
Number of subjects: 117
Study: 17869291

Group type: EXPERIMENTAL
Intervention: Vardenafil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Erection Quality Scale
Number of subjects: 0
Study: 16926937

Group type: EXPERIMENTAL
Intervention: Preventive primary care outreach interventions
Number of subjects: 14911
Study: 12482164

Group type: EXPERIMENTAL
Intervention: Estrostep® (norethindrone acetate/ethinyl estradiol)
Number of subjects: 591

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 591
Study: 9579448

Group type: EXPERIMENTAL
Intervention: Transdermal estradiol 50 microg/day
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Oral tamoxifen 20 mg/day
Number of subjects: 45

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 45
Study: 7648962

Group type: EXPERIMENTAL
Intervention: 10% Intralipid (nine patients)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 26.7% Glucose (nine patients)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Saline infusion (control group)
Number of subjects: 27
Study: 2668227

Group type: EXPERIMENTAL
Intervention: Pain Suppressor Unit (cranial electrotherapy stimulator)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 52007

Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 12
Study: 31306800

Group type: EXPERIMENTAL
Intervention: Entecavir
Number of subjects: 12378

Group type: COMPARATOR
Intervention: Nonentecavir HBV nucleos(t)ide analogue
Number of subjects: 12378

Group type: COMPARATOR
Intervention: Both groups (Entecavir and Nonentecavir)
Number of subjects: 12378
Study: 31546856

Group type: EXPERIMENTAL
Intervention: iPad-enhanced aerobic exercise
Number of subjects: 27

Group type: COMPARATOR
Intervention: aerobic exercise-only
Number of subjects: 27
Study: 28304219

Group type: EXPERIMENTAL
Intervention: TAVR (transcatheter aortic-valve replacement)
Number of subjects: 1746

Group type: COMPARATOR
Intervention: Surgical aortic-valve replacement
Number of subjects: 1746

Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 1746

Group type: EXPERIMENTAL
Intervention: TAVR
Number of subjects: 1746

Group type: EXPERIMENTAL
Intervention: Both TAVR and Surgery
Number of subjects: 1746
Study: 24690383

Group type: EXPERIMENTAL
Intervention: SeqA60% (60% of 1RM)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: SeqA80% (80% of 1RM)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: SeqB60% (60% of 1RM)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: SeqB80% (80% of 1RM)
Number of subjects: 13
Study: 23881301

Group type: EXPERIMENTAL
Intervention: Affected kidneys (ARFI imaging)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Contralateral kidneys (ARFI imaging)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Healthy kidneys (ARFI imaging)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Affected kidneys with secondary reflux (ARFI imaging)
Number of subjects: 28
Study: 21899210

Group type: EXPERIMENTAL
Intervention: Betamethasone i.m. (BSP 2 mg and BDP 5 mg)
Number of subjects: 10
Study: 19853726

Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 25928

Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 25928

Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 25928

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 25928

Group type: COMPARATOR
Intervention: Duloxetine
Number of subjects: 25928

Group type: COMPARATOR
Intervention: Fluoxetine
Number of subjects: 25928

Group type: COMPARATOR
Intervention: Fluvoxamine
Number of subjects: 25928

Group type: COMPARATOR
Intervention: Paroxetine
Number of subjects: 25928

Group type: COMPARATOR
Intervention: Reboxetine
Number of subjects: 25928
Study: 16717333

Group type: EXPERIMENTAL
Intervention: Sevoflurane at 1.0 MAC (BIS 40-50)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Desflurane at 1.0 MAC (BIS 40-50)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Sevoflurane at 1.2 MAC (BIS 40-50)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Desflurane at 1.6 MAC (BIS 20-30)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Sevoflurane at 1.8 MAC (BIS 20-30)
Number of subjects: 44
Study: 29932416

Group type: EXPERIMENTAL
Intervention: Bretol® patch (test drug)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Hokunalin® patch (reference drug)
Number of subjects: 27
Study: 11810114

Group type: EXPERIMENTAL
Intervention: Noninvasive positive pressure ventilation (NPPV)
Number of subjects: 354
Study: 9131723

Group type: EXPERIMENTAL
Intervention: Clozapine (up to 450 mg)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Zotepine (up to 450 mg)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (13 matched healthy persons)
Number of subjects: 25
Study: 7703598

Group type: EXPERIMENTAL
Intervention: Glucose (1 g/kg body wt)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Fructose (1 g/kg body wt)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Glucose and Fructose
Number of subjects: 13